Journavx

Journavx is a non‑opioid oral painkiller approved for adults with moderate‑to‑severe acute pain. It blocks sodium‑channel pain signals in the body, relieving pain without addiction risk.

Molecule Details :

  • Molecule Name :

    Suzetrigine
  • Innovator :

    VERTEX PHARMACEUTICALS INC
  • Approval Date :

    30-Jan-25
  • NCE-1 Date :

    30-Jan-29
  • NCE Date :

    30-Jan-30
  • Dosage Form :

    Oral Tablet
  • Strength :

    50MG
  • Therapeutic Category :

    Analgesic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    78
  • 2026 :

    291
  • 2027 :

    628
  • 2028 :

    1,082
  • 2029 :

    1,587
  • 2030 :

    2,133
  • 2031 :

    2,585
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?